Schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma

Summary

Schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma (MONDO:0004408) is a disease. A subtype of nodular ganglioneuroblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma
Mondo ID	MONDO:0004408
DOID	DOID:7951
NCIT	C42059
UMLS	C1516760
MedGen	275792
GARD	0023987
Is cancer (heuristic)	no

Also known as: composite ganglioneuroblastoma, Schwannian Stroma-rich and Stroma-poor

Disease family

This is a subtype of nodular ganglioneuroblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › embryonal neoplasm › primitive neuroectodermal tumor › neuroblastic tumor › ganglioneuroblastoma › nodular ganglioneuroblastoma › schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma

Related subtypes (1): stroma-dominant and stroma-poor composite ganglioneuroblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.